Drugs / Glecirasib
Glecirasib
English name glecirasib
also known as
JAB-21822
Small molecule targets KRAS via inhibition
Trials 15
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT06838338 | Mar 2025 → Mar 2026 overdue | colorectal cancer | Jian Li | Active not recruiting | No outcome recorded |
| Phase 1 | NCT06162169 | Nov 2023 → Feb 2024 | — | Allist Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT05920941 | Jul → Aug 2023 | — | Allist Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT05875493 | May → Jun 2023 | — | Allist Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1/26 trials | ||||||
| Phase 1/2 | NCT07339839 | Mar 2026 → Sep 2027 expected | non-small cell lung carcinoma | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT05276726 | Aug 2022 → Feb 2026 overdue | non-small cell lung carcinoma | Allist Pharmaceuticals, Inc. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05288205 | Apr 2022 → Mar 2026 overdue | acute myeloid leukemia, KRAS gene mutation, colorectal cancer, non-small cell lung carcinoma, pancreatic ductal adenocarcinoma | Allist Pharmaceuticals, Inc. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05194995 | Feb 2022 → Apr 2025 overdue | appendix cancer, small intestine cancer | Allist Pharmaceuticals, Inc. | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT05002270 | Sep 2021 → Feb 2025 | non-small cell lung carcinoma | Jacobio Pharmaceuticals Co., Ltd. | Completed | No outcome recorded |
| Phase 1/2 | NCT05009329 | Jul 2021 → May 2026 overdue | non-small cell lung carcinoma | Allist Pharmaceuticals, Inc. | Active not recruiting | No outcome recorded |
| Phase 24 trials | ||||||
| Phase 2 | NCT07827261 | Sep 2026 → Dec 2028 expected | non-small cell lung carcinoma | Sichuan Baili Pharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07164170 | Sep 2025 → Dec 2028 expected | non-small cell lung carcinoma | Abbisko Therapeutics Co, Ltd | Recruiting | No outcome recorded |
| Phase 2 | NCT06563999 | Nov 2024 → Nov 2027 expected | lung carcinoma | Sun Yat-sen University | Recruiting | No outcome recorded |
| Phase 2 | NCT06008288 | Oct 2023 → Dec 2026 expected | malignant pancreatic neoplasm | Allist Pharmaceuticals, Inc. | Recruiting | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT06416410 | Aug 2024 → Sep 2026 overdue | non-small cell lung carcinoma | Allist Pharmaceuticals, Inc. | Recruiting | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT07601048 Comparator | Jun 2026 → May 2028 expected | — | Shandong Suncadia Medicine Co., Ltd. | Not yet recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2025-12-05 | Allist Pharmaceuticals, Inc. | Results KRAS G12C抑制剂戈来雷塞治疗晚期结直肠癌研究成果亮相《柳叶刀》，为患者带来新曙光 allist.com.cn ↗
单药组客观缓解率（ORR）为22.7%，疾病控制率（DCR）达86.4%；联合治疗组ORR为50.0%，DCR为87.0%。 |
| 2025-11-29 | Allist Pharmaceuticals, Inc. | Results 新曙光 | 国际首例 ：KRAS G12C抑制剂戈来雷塞联合SHP2抑制剂的口服双靶联合治疗研究成果荣登《柳叶刀·呼吸病学》 allist.com.cn ↗ |
| 2025-08-21 | Abbisko Therapeutics Co, Ltd | Regulatory Abbisko Therapeutics Announces IND Clearance from the CDE for ABSK043 in Combination with Glecirasib from Allist Pharmaceuticals, for the Treatment of NSCLC abbisko.com ↗ |
All press releases naming this drug 5 releases
| Date | Issuer | Release |
|---|---|---|
| 2025-12-05 | Allist Pharmaceuticals, Inc. | KRAS G12C抑制剂戈来雷塞治疗晚期结直肠癌研究成果亮相《柳叶刀》，为患者带来新曙光 allist.com.cn ↗ |
| 2025-11-29 | Allist Pharmaceuticals, Inc. | 新曙光 | 国际首例 ：KRAS G12C抑制剂戈来雷塞联合SHP2抑制剂的口服双靶联合治疗研究成果荣登《柳叶刀·呼吸病学》 allist.com.cn ↗ |
| 2025-11-03 | Abbisko Therapeutics Co, Ltd | Abbisko Therapeutics Completes First Patient Dosing in a Phase II Study of ABSK043, an Oral Small-Molecule PD-L1 inhibitor, in Combination with Glecirasib for the Treatment of NSCLC abbisko.com ↗ |
| 2025-08-21 | Abbisko Therapeutics Co, Ltd | Abbisko Therapeutics Announces IND Clearance from the CDE for ABSK043 in Combination with Glecirasib from Allist Pharmaceuticals, for the Treatment of NSCLC abbisko.com ↗ |
| 2025-03-24 | Abbisko Therapeutics Co, Ltd | Abbisko Therapeutics and Allist Pharmaceuticals Enter into a Cooperation Agreement to Explore ABSK043 in Combination Glecirasib for the Treatment of NSCLC abbisko.com ↗ |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 19 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | glecirasib | “Our group previously reported promising efficacy and safety results for glecirasib (JAB-21822), a novel KRASG12C inhibitor, in phase I/II trials involving solid tumors...” PMID 42384131 ↗ Jul 2026 |
| Known as | JAB-21822 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06008288 ↗ |
| Action | Inhibit | “a new covalent oral KRAS-G12C inhibitor” PMID 39762419 ↗ Jan 2025 |
| Modality | Small molecule | — CHEMBL5314518 ↗ |
| Route | Oral | “JAB-21822 will be administered orally” NCT05009329 ↗ |
| Target | KRAS | “a new covalent oral KRAS-G12C inhibitor” PMID 39762419 ↗ Jan 2025 |